2,3-二氢-1-苯并呋喃-2-甲酰氯 | 27347-32-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 中文名称: 2,3-二氢-1-苯并呋喃-2-甲酰氯
• 英文名称: 2,3-dihydrobenzofuran-2-carbonyl chloride
• 英文别名: 2.3-Dihydro-benzofuran-carbonsaeure-(2)-chlorid；2,3-Dihydro-1-benzofuran-2-carbonyl chloride
• CAS: 27347-32-6
• 化学式: C₉H₇ClO₂
• 分子量: 182.606
• InChiKey: QZVPHVMVWZKULP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39,S45
• 危险类别码：
  R34
• 海关编码：
  2932999099
• 危险品运输编号：
  UN 3265

SDS

Name:	2 3-Dihydro-1-benzofuran-2-carbonyl chloride tech Material Safety Data Sheet
Synonym:
CAS:	27347-32-6

Section 1 - Chemical Product MSDS Name:2 3-Dihydro-1-benzofuran-2-carbonyl chloride tech Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
27347-32-6	2,3-Dihydro-1-benzofuran-2-carbonyl ch		unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 27347-32-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H7ClO2
Molecular Weight: 182.61

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 27347-32-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,3-Dihydro-1-benzofuran-2-carbonyl chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3265
Packing Group: III
IMO
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3265
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE LIQUID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3265
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 27347-32-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 27347-32-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 27347-32-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,3-二氢-1-苯并呋喃-2-甲酰氯 在 4-二甲氨基吡啶 、 三乙胺 、 三甲基硅烷化重氮甲烷 作用下， 以 二氯甲烷 为溶剂， 生成 6-(2,3-Dihydro-benzofuran-2-yl)-5-(4-nitro-phenyl)-pyrimidine-2,4-diamine
  参考文献：
  名称：

  Optimization of 2,4-diaminopyrimidines as GHS-R antagonists: Side chain exploration

  摘要：

  The synthesis and structure-activity relationships of the 4- and 6-substituents of 2,4-diaminopyrimidine-based growth hormone secretagogue receptor (GHS-R) antagonists are described. Diaminopyrimidines with 6-norbornenyl (4n) and 6-tetrahydrofuranyl (4p) substitutents were found to exhibit potent GHS-R antagonism and good selectivity (similar to 1000-fold) against dihydrofolate reductase. (C) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.01.012
• 作为产物：
  描述：

  烯丙基苯基醚 在 sodium hypochlorite 、 氯化亚砜 、 2,2,6,6-四甲基哌啶氧化物 、 2,2,2-三氟苯乙酮 、 双氧水 、 碳酸氢钠 、 potassium bromide 作用下， 以 四氢呋喃 、 水 、 硝基苯 、 乙腈 、 叔丁醇 为溶剂， 反应 28.0h， 生成 2,3-二氢-1-苯并呋喃-2-甲酰氯
  参考文献：
  名称：

  烯丙基苯酚的氧化环化反应绿色有机催化合成二氢苯并呋喃

  摘要：

  作为专题“现代合成中的环化策略”的一部分发布 抽象的 提出了一种绿色廉价的方案，用于通过邻烯丙基苯酚的有机催化氧化合成二氢苯并呋喃。使用2,2,2-三氟苯乙酮和H 2 O 2作为氧化系统，导致了一种非常有用的合成方法，其中各种取代的邻烯丙基苯酚均以高收率环化。 提出了一种绿色廉价的方案，用于通过邻烯丙基苯酚的有机催化氧化合成二氢苯并呋喃。使用2,2,2-三氟苯乙酮和H 2 O 2作为氧化系统，导致了一种非常有用的合成方法，其中各种取代的邻烯丙基苯酚均以高收率环化。

  DOI：

  10.1055/s-0036-1588998

文献信息

• Substituted Pyrrolidines and Methods of Use
  申请人：AbbVie S.à.r.l.

  公开号：US20180099931A1

  公开（公告）日：2018-04-12

  The invention discloses compounds of Formula (I) wherein R 1 , R 2 , R 2A , R 3 , R 3A , R 4 , R 4A , and R 5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

  该发明公开了式（I）的化合物 其中R 1 ，R 2 ，R 2A ，R 3 ，R 3A ，R 4 ，R 4A 和R 5 如本文所定义。本发明涉及化合物及其在囊性纤维化治疗中的应用，其生产方法，包含相同化合物的药物组合物，以及通过给予该发明的化合物来治疗囊性纤维化的方法。
• [EN] SUBSTITUTED MORPHOLINE AND THIOMORPHOLINE DERIVATIVES<br/>[FR] DÉRIVÉS DE MORPHOLINE ET DE THIOMORPHOLINE SUBSTITUÉS
  申请人：LUNDBECK & CO AS H

  公开号：WO2005087754A1

  公开（公告）日：2005-09-22

  The present invention relates to morpholine and thiomorpholine derivatives of the general formula I or pharmaceutically acceptable salts thereof and their use.

  本发明涉及一般式I的吗啉和硫代吗啉衍生物或其药用盐及其用途。
• Method of Preparation of Benzofuran-2-Carboxylic Acid -Amide
  申请人：Clark William M.

  公开号：US20080262224A1

  公开（公告）日：2008-10-23

  This invention relates to a method of preparation of benzofuran-2-carboxylic acid (S)-3-methyl- 1 -[(4S,7R)-7-methyl-3-oxo-1-(pyridine-2-sulfonyl)-azepan-4-ylcarbamoyl]-butyl}-amide.

  这项发明涉及一种制备苯并呋喃-2-羧酸(S)-3-甲基-1-[(4S,7R)-7-甲基-3-氧代-1-(吡啶-2-磺酰基)-氮杂庚-4-基甲酰]-丁基}-酰胺的方法。
• Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists
  申请人：Kosogof Christi

  公开号：US20050171131A1

  公开（公告）日：2005-08-04

  The present invention is related to compounds of formula (I), or a therapeutically suitable salt or prodrug thereof, the preparation of the compounds, compositions containing the compounds and the use of the compounds in the prevention or treatment of disorders regulated by the action of ghrelin receptor, including Prader-Willi syndrome, eating disorder, weight gain, weight-loss maintainance following diet and exercise, obesity, and disorders associated with obesity such as noninsulin dependent diabetes mellitus.

  本发明涉及式(I)的化合物，或其治疗上适用的盐或前药，所述化合物的制备，含有所述化合物的组合物以及在预防或治疗由胃泌素受体调节的疾病中使用所述化合物，包括普拉德-威利综合征、进食障碍、体重增加、饮食和锻炼后体重减轻维持、肥胖，以及与肥胖相关的疾病，如非胰岛素依赖型糖尿病。
• Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors
  申请人：Parker C. Janice

  公开号：US20050043292A1

  公开（公告）日：2005-02-24

  The invention relates to new therapeutically active and selective inhibitors of the enzyme dipeptidyl peptidase-IV (“DPP-IV”), pharmaceutical compositions comprising the compounds and the use of such compounds for treating diseases that are associated with proteins that are subject to processing by DPP-IV, such as Type 2 diabetes, metabolic syndrome (syndrome X or insulin resistance syndrome), hyperglycemia, impaired glucose tolerance, glucosuria, metabolic acidosis, arthritis, cataracts, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, diabetic cardiomyopathy, Type 1 diabetes, obesity, conditions exacerbated by obesity, hypertension, hyperlipidemia, atherosclerosis, osteoporosis, osteopenia, frailty, bone loss, bone fracture, acute coronary syndrome, infertility due to polycystic ovary syndrome, short bowel syndrome, anxiety, depression, insomnia, chronic fatigue, epilepsy, eating disorders, chronic pain, alcohol addiction, diseases associated with intestinal motility, ulcers, irritable bowel syndrome, inflammatory bowel syndrome and to prevent disease progression in Type 2 diabetes. The invention also relates to a method of identifying an insulin secretagogue agent for diabetes.

  该发明涉及新的具有治疗活性和选择性的酶二肽基肽酶-IV（“DPP-IV”）抑制剂，包括这些化合物的药物组合物以及利用这些化合物治疗与受DPP-IV加工的蛋白质相关的疾病，如2型糖尿病、代谢综合征（综合征X或胰岛素抵抗综合征）、高血糖、糖耐量受损、糖尿病、代谢性酸中毒、关节炎、白内障、糖尿病性神经病变、糖尿病性肾病、糖尿病性视网膜病变、糖尿病性心肌病、1型糖尿病、肥胖、由肥胖恶化的疾病、高血压、高脂血症、动脉粥样硬化、骨质疏松症、脆弱性、骨质流失、骨折、急性冠状动脉综合征、多囊卵巢综合征导致的不孕症、短肠综合征、焦虑、抑郁症、失眠、慢性疲劳、癫痫、进食障碍、慢性疼痛、酒精成瘾、与肠道蠕动有关的疾病、溃疡、肠易激综合征、炎症性肠病以及预防2型糖尿病疾病进展的方法。该发明还涉及一种用于识别糖尿病胰岛素分泌素的方法。